(Q35095147)

6 August 2017

1 reference

title

Tyrosine kinases as targets in cancer therapy - successes and failures (English)

1 reference

6 August 2017

Peter Traxler

1

1 reference

PubMed ID

12667099

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Therapeutic Targets

6 August 2017

1 reference

6 August 2017

7

1 reference

6 August 2017

215-234

1 reference

6 August 2017

2

1 reference

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

ATP site-directed competitive and irreversible inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Anti-epidermal growth factor receptor drugs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

ZD1839: targeting the epidermal growth factor receptor in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Tumor angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Involvement of platelet-derived growth factor in disease: development of specific antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Fibroblast growth factors in cancer: therapeutic possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Signaling angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.2.215

21 January 2018

Identifiers

DOI

10.1517/14728222.7.2.215

1 reference

6 August 2017

1 reference

PubMed ID

12667099